Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform Blue Bell, Pa. — Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new class of chemical...
Industry veterans David Scheer and Brian Halak join Board of Directors Philadelphia, PA — November 12, 2025 — ThirdLaw Molecular, Inc. today announced its new name change, Ladder Bio Inc., reflecting the company’s mission to pioneer Spiroligomer™ therapeutics...
Media Contact:Alison Guzzio484-459-3243Alison.guzzio@thirdlaw.tech Philadelphia, PA – May 7, 2025 – ThirdLaw Molecular Inc., a pioneering drug discovery company, today announced that DJ Bernsteel, PhD, will present groundbreaking research on screening a 4.5...
Media Contact: Alison Guzzio 484-459-3243 Alison.guzzio@thirdlaw.tech ThirdLaw Molecular has pioneered the development of Spiroligomer™ molecules – an entirely new, synthetic, therapeutic modality that reimagines molecular therapeutics Spiroligomer™ molecules combine...
Award winning medicinal chemist, Dr. Joseph Vacca, joins Third Law Molecular LLC as Scientific Advisor, bringing deep drug discovery and development experience, to advance its groundbreaking new platform for targeted drug discovery. Joins Dr. Tomi Sawyer, Peptide Drug...
